Abstract:Objective:To test our hypothesis that reversion of insulin resistance by rhein might contribute to its therapeutic effect on diabetic nephropathy(DN) the effects of rhein and rosiglitazone on metabolic disorders and renal lesion in diabetic db/db mice were compared, and the mechanism of rhein on preventing the development of DN was also investigated Methodology:Diabetic db/db mice were continuously treated with rhein 120mg/(kg·d) or rosiglitazone 4mg/(kg·d) for 12 weeks The body weight, serum glucose and lipid were detected at the end of the study Renal histopathology was evaluated under light microscopy and immunohistochemistry staining Mitochondrial morphology was observed under electronic microscopy The expression of mRNA was determined by real time RT PCR Results:Compared with the untreated diabetic conrols, both of rhein and rosiglitazone led to similar amelioration of glomerular mesangial expansion and extracelluar matrix accumulation, as well as reduction of blood glucose level However, the diverse changers were observed in lipid metabolism after two agents treatment Rhein markedly decreased the body weight of mice [(45 0±2 60g vs (49 9±1 00g, P 0 01] and the level of plasma cholesterols [(2 1±0 20 vs (2 8±0 6 mmol/L, P 0 01], while rosiglitazone significantly increased the body weight [(52 9±2 2g vs (49 9±1 0g, P 0 01] and cholesterols [(5 5±0 6 vs (2 8±0 6 mmol/L, P 0 01] The level of low density lipoprotein (LDL was also enhanced after rosiglitazone treatment [(0 45±0 11 vs (0 13±0 04 mmol/L, P 0 01] while mild fell after rhein treatment The number of mitochondrial was decreased and the structure blurry in renal tubular epithelia from db/db mice, and which were markedly ameliorated by rhein and mildly by rosiglitazone The expression of PPARγ was down regulated in the fat and muscle of db/db mice, while up regulated after both rhein and rosiglitazone treatment The expression of resistin, a linkage between obesity and insulin resistance, was unexpectantly reduced in db/db mice and mildly decreased in fat and markedly increased in muscle after rhein or rosiglitazone treatment, confusing the role of resistin on insulin resistance The expression of fatty acid translocase (FAT/CD36) was found to be up regulated in fat and muscle of db/db mice, and attenuated by both two agents However, the effect of rhein was much more stronger than rosiglitazone Conclusion:The similar renal protective effect of rhein compared with rosiglitazone gave the evidence that reversion of insulin resistance was attributed to the prevention of DN In addition, the improvement of lipidemia by rhein might provide a better way for diabetic metabolic disorders than by rosiglitazone, which was shown an adverse consequence of hyperlipidemia and weight gain

Rhein reverses the diabetic phenotype of mesangial cells over-expressing the glucose transporter (GLUT1) by inhibiting the hexosamine pathway.

Effect of Rhein on Glucose Transporter-1 Expression and Its Function in Glomerular Mesangial Cells.

Inhibition of Glucose Transporter 1 Overexpression in Mesangial Cells by Rhein

[Effects of Rhein on the Function of Human Mesangial Cells in High Glucose Environment].

Rhein protects retinal Müller cells from high glucose-induced injury via activating the AMPK/Sirt1/PGC-1α pathway

Glucose Transporter in Human Glomerular Mesangial Cells Modulated by Transforming Growth Factor Beta and Rhein

Improvement of Glucose Tolerance by Rhein with Restored Early-Phase Insulin Secretion in Db/db Mice

Inhibitory Effect of Rhein on Renal Fibrosis in Diabetic Nephropathy Rats

Rhein Protects Pancreatic Beta-Cells From Dynamin-Related Protein-1-Mediated Mitochondrial Fission And Cell Apoptosis Under Hyperglycemia

Rhein Inhibits Renal Tubular Epithelial Cell Hypertrophy and Extracellular Matrix Accumulation Induced by Transforming Growth Factor Beta1.

Rhein Improves Renal Lesion and Ameliorates Dyslipidemia in Db/Db Mice with Diabetic Nephropathy

Rhein retards the progression of type 2 diabetic nephropathy in rats

Rhein inhibits integrin-linked kinase expression and regulates matrix metalloproteinase-9/tissue inhibitor of metalloproteinase-1 ratio in high glucose-induced epithelial-mesenchymal transition of renal tubular cell

The Molecular Mechanism of Rhein in Diabetic Nephropathy

Related Mechanisms of Rhein Improving Glucose and Lipid Metabolism

Improvement of Diabetic Metabolic Disorders Ameliorate the Renal Lesion in Db/db Mice:Comparison Between Rhein and Rosiglitazone

Rhein alleviates advanced glycation end products (AGEs)-induced inflammatory injury of diabetic cardiomyopathy in vitro and in vivo models

Therapeutic Effect of Rhein on Diabetic Nephropathy in Db/db Mice

Gut Microbiota Play an Essential Role in the Antidiabetic Effects of Rhein

[Effect of Early Intervention with Rhein on Islet Function in Db/db Mice].

Rhein for treating diabetes mellitus: A pharmacological and mechanistic overview